In this report, we describe in detail the evolving procedures to optimize humanized mouse cohort generation, including optimal conditioning, choice of lineage for engraftment, threshold for successful engraftment, HNSCC tumor implantation, and immune and stroma cell analyses. We developed a dual infusion protocol of human hematopoietic stem and progenitor cells (HSPCs) and mesenchymal stem cells (MSCs), leading to incremental human bone marrow engraftment, and exponential increase in mature peripheral human immune cells, and intratumor homing that includes a more complete lineage reconstitution. Additionally, we have identified practical rules to predict successful HSPC/MSC expansion, and a peripheral human cell threshold associated with bone marrow engraftment, both of which will optimize cohort generation and management. The tremendous advances in immune therapy in cancer have made the need for appropriate and standardized models more acute than ever, and therefore, we anticipate that this manuscript will have an immediate impact in cancerrelated research. The need for more representative tools to investigate the human tumor microenvironment (TME) has led to the development of humanized mouse models.
| INTRODUCTION
The tumor microenvironment (TME) is a critical interface in cancer biology and immunology, dictating not only tumorigenesis, but also tumor progression and susceptibility to conventional and immunedirected therapies. Immune-directed therapies have greatly advanced patient care but are limited by modest single-agent efficacy, lack of predictive biomarkers, and uncharacterized mechanisms of resistance limiting rational combinatorial strategies. In head and neck squamous cell carcinoma (HNSCC), programmed cell death 1 (PD-1) inhibitors are approved for recurrent/relapsed patients but have response rates of only ∼25%.
1 These barriers highlight the need for appropriate models to better understand the biologic basis of disease, identify and prioritize targets, and assist in devising more effective therapies.
To faithfully represent the human TME and develop therapies, a model must be capable of recapitulating the interactions between tumor and stromal cells observed in the patient. Cultured cell lines lack stromal cells and poorly predict patient response. 2 Patient-derived xenografts (PDX) implanted on immunocompromised mice produce a more realistic TME, but the stroma and immune cells interacting with the growing tumor are of mouse origin, reconstitute only a partial TME while fostering xenogeneic tumor growth, and do not accurately represent a human environment. 3, 4 To overcome these obstacles, several humanized mouse (HM) models have been developed over the past 15 years. [5] [6] [7] [8] [9] [10] [11] These models either infused immune cells directly or engrafted human hematopoietic precursors, so that ultimately stromal tissue interacts with implanted tumors to more accurately recreate the patient TME. 11, 12 We previously reported the generation of a HM xenograft model. 13 Purified human Myc and Bcl-2 proteins were used to drive in vitro expansion of umbilical cord blood-derived hematopoietic stem and progenitor cells (HSPCs) that were injected into previously irradiated NOD/SCID/IL2rg −/− (NSG) mice to produce animal cohorts with some human immune system components. 14 Tumor tissue surgically resected from HNSCC patients was implanted onto the flanks of these HM and we observed that human T and B cells originating in the engrafted human bone marrow infiltrated these growing tumors. We also analyzed tumor mRNA expression and showed that the drift in gene expression typically observed in PDX was partially reversed. 3, 15 This model was limited by a low abundance of human immune cells within the mouse bone marrow and infiltrating the implanted xenografts. Some immune cell subtypes critical in immune biology and therapy, for example, CD8, regulatory T (Treg) cells, and myeloid derived suppressor cells (MDSCs)
were rare or undetectable.
Here, we report a significantly improved HM xenograft model, constructed from patient-derived tumors implanted on allogeneic or mismatched humanized mice (mHM). To avoid manipulating the HSPCs and thus minimizing changes to the precursor environment, we focused on optimizing in vitro expansion and on identifying additional lineages for concurrent engraftment. We isolated HSPCs from donated cord blood, cultured them in cytokine-containing expansion media, and produced sufficient HSPCs to engraft large cohorts of mice.
We also identified a mesenchymal stem cell (MSC)-like population within the expanding HSPCs which, when engrafted with the HSPCs, yields mHM with an incrementally greater proportion of human immune cells within their bone marrow. These produce exponentially more robust populations of lymphoid and myeloid cells in HM blood, consistent with the reported role of MSCs. 16 To standardize model and cohort generation we sought to identify a peripheral mouse blood parameter that would accurately predict adequate humanization prior to tumor implantation. This is critical in reducing model variability, a consistent obstacle in HM platforms that limits their utility. 11 A correlation of peripheral blood profiles of live animals with necropsy analysis of humanized bone marrow content allowed the identification of a threshold level of humanization at which mice can be considered experimentally useful. In these well-humanized mice, human monocytes, T cells, and B cells migrate into implanted HNSCC tissue creating a TME that more accurately resembles that of the originator patient. 
| Immunohistochemistry (IHC)
IHC analyses were performed as previously described. 13 Briefly, slides 
| Statistical analysis
In vitro and in vivo experiments were compared with a two-group t- method with a Akaike's Information Criterion (AIC) penalty was applied to the data to detect optimal changepoints, or the point at which the mean of the values changes. 18 3 | RESULTS
| HSPC isolation and expansion
We isolated HSPCs from donated cord blood by CD34+ selection, followed by culture in expansion media containing Flt3, stem cell factor (SCF), IL-3, IL-6, and LDL. We observed substantial variability in the percentage of the resident HSPC population in donated cords as well as in its potential for in vitro expansion. The percentage of HSPCs among the cord blood leukocytes, HSPC density (HSPCs/mL), and the total number of HSPCs purified from a cord did not independently predict HSPC expansion potential (P = 0.90, P = 0.22 and 0.22, respectively; Table 1 ), and neither did cord volume or the percentage of living cells, both of which had narrower ranges (t-test, P = 0.78 and 0.87; data not shown). It takes 3-4 days in culture to be able to predict if a given cord will be responsive, and therefore capable of sufficient expansion for engraftment into a cohort of mice. By this point in the expansion, the cell population from responsive cords increased approximately fivefold, from an initial average of 560 000 HSPCs to 2 750 000 HSPCs, while that of nonresponsive cords failed to even double, rising from an average of 370 000 HSPCs to 700 000 (P < 0.01; Figure 1A ). A combination of features (initial HSPC population and expansion over the first 3-4 days) predicted responsive cords according to one of two sets of conditions: (i) >500 000 HSPCs and ≥3-fold expansion, or (ii) >200 000 HSPCs and at least ≥5-fold expansion. This rule correctly identified 62% and 85% responsive and non-responsive cords, respectively, yielding an overall 73% chance of a correct prediction.
Among responsive cords, the number of HSPCs increased rapidly for several days before plateauing around the ninth day of expansion, as increased differentiation overtook HSPC division (as depicted in the expansion of HM013, Figure 1B) . The HSPC population in responsive cords overall increased by an average of 23-fold, to almost 13 000 000 cells, and the cell number among these cords ranged from 6 000 000 to 36 000 000. The number of HSPCs in non-responsive cords increased less than fourfold, to only 1 250 000 cells on average (range zero to 2 750 000 HSPCs). In summary, the behavior after 3-4 days in culture but no baseline characteristic identified cords amenable to appropriate HSPC expansion.
| Titration of HSPCs per mouse and mHM cohort size
Following this expansion protocol, we were able to generate HSPC populations of an average of ∼13 000 000 cells, thus enabling the engraftment of large mHM cohorts using 400 000 HSPCs per mouse ( Figure 1C ). We have generated cohorts using as few as ∼300 000 (HM057 and HM069) or as many as 1 000 000 HSPCs per mouse (HM025) and observed no significant variation in overall mouse humanization. On the other hand, when we engrafted a cohort (HM071) with only 150 000 HSPCs/mouse, the resulting mice showed poor humanization (with an average of only 7.1% human immune cells in their bone marrow).
| Immediate versus delayed utilization of cord blood precursors
We next assessed the feasibility of cryopreserving aliquots of partially expanded HSPCs from responsive cords, giving us the capability of performing experiments with cells from the same source at different timepoints. To this end, we purified and cryopreserved successfully expanding HSPCs and generated a bank of cells from responsive cords for future cohort generation. We successfully generated several cohorts (HM059, HM071, HM084, and HM060) from frozen HSPCs.
Although on average only 20% of the cells tolerate the freezing process, the surviving HSPCs remained capable of undifferentiated division in culture for several days after thawing (shown for the average of all cryopreserved HSPCs and for HM084 in Figure 1D ).
Additionally, we observed no reduction in the degree of mouse humanization in the HM059 cohort (see Figure 2A ). Data not shown for cord volume (P = 0.78) and percentage of living cells (P = 0.87).
| MSC isolation and expansion

FIGURE 1
In vitro amplification of HSPCs and MSCs; pre-engraftment mouse irradiation. A, Growth curves of HSPCs purified from responsive and non-responsive cords. Significant differences in proliferation can be seen after several days in culture (mid-expansion). B, Flow cytometry depicting the amplification of HSPCs during in vitro expansion and, by Day 13 , the gradual loss of HSPCs due to increased immune cell differentiation. The total number of cells in the sample is recorded above each graph, along with the percentage of those cells (in green, corresponding to the green box superimposed on the graph) that are HSPCs. C, Chart comparing potential and actual sizes of the mHM cohorts after HSPC expansion, based on an injection of 400 000 HSPCs per mouse. Cohorts HM057 and HM069 were generated using 300 000 cells/ mouse, so their actual size is greater than their potential size. D, HSPC loss due to freezing and subsequent re-expansion after removal of the cells from cryopreservation. Overall averages for all subsequently expanded cryopreserved HSPCs (red) and for the HM084 HSPCs (blue) are shown. For HM084, the cell numbers at the blue and green points on this graph are represented by cytometry, which shows pre-and post-freeze 
| Pre-engraftment irradiation
Whole-body irradiation is commonly used to help direct human precursor cells toward mouse bone marrow. 19 To determine an ideal dose for optimal conditioning and minimal radiation-induced mouse mortality, we irradiated different groups of mice with 1.5, 1.8, 2.0, 2.2, or 2.4 Gy prior to the injection of 400 000 expanded HSPCs from the same cord, then compared mortality and humanization ( Figure 1I ).
Although increased radiation doses led to small increases in humanization, mice receiving greater than 1.5 Gy were 2.8 times as likely to die as those receiving 1.5 Gy (3 of 16, or 19%, vs 8 of 15, or 53%), encouraging the selection of a 1.5 Gy dose. To ensure all mice received an equivalent dose of radiation, we used containers designed to minimize mouse movement beneath the irradiation source.
| mHM cohort generation
We have generated and analyzed mouse humanization on 20 mHM cohorts (Table 1 and Figure 2A) . We created the initial six cohorts using Figure 4D) . 20 It appears that macrophage differentiation may mimic that frequently observed in patient tumors. M1 macrophages appear more predominantly in the CUHN013 patient tumor and xenografts; while M2 macrophages are more often observed in the CUHN022 patient tumor and xenografts ( Figure 4E ). Some cell types, such as macrophages, NK, Treg, and cytotoxic T cells, are much more 
| Establishing a threshold to predict adequate mouse humanization
| DISCUSSION
The utility of a cancer model system lies in its ability to recreate conditions in the patient tumor and its microenvironment, ultimately enabling biologic discovery and therapy development. Although traditional mouse xenograft models can partially meet this need, they cannot recapitulate interactions between cancer and immune cells within the TME. 21, 22 Over the past decade, humanized mouse xenograft models have been developed to address this challenge. 23 However, reconstitution of a human immune system within a mouse model depends on interrelated factors that must be coordinated to maximize the utility of this system.
There are several immunocompromised mouse strains that can be used in humanization studies. 24 The NSG mouse is particularly suitable for this process, because it lacks T cells, B cells, NK cells, and mature
macrophages, yet remains hardy enough to undergo pre-engraftment irradiation without undue mortality. 25, 26 Although some groups have reported that species-specific activity of some mouse cytokines prevents maturation of myeloid cells within the NSG mouse, 27 ,28 it appears the presented dual HSPC-MSC engraftment process can, at least in part, overcome this obstacle; we can readily identify monocytes in the blood and macrophages infiltrating into tumors of well-humanized animals. Potential approaches for further improvements in myeloid differentiation include utilization of existing transgenic mouse strains containing human cytokines. 29, 30 Several factors contribute to the substantial variability in the extent to which individual mice in a given mHM cohort are humanized. Although published humanization protocols recommend pre-engraftment mouse 31, 32 we have produced the humanized mice described in our results above using 1.5 Gy without excessive mouse (and subsequent cohort) attrition. Even at this lower dose, it is not atypical for 10% of the irradiated mice to die within a week of conditioning and engraftment. Although it is possible that higher doses produce greater consistency in humanization, mouse mortality can be as great as 50%, which has a substantial impact on cohort size and experimental utility.
Humanization variability within individual cohorts could also be caused by movement of mice into and out of regions of increased radiation intensity.
We have minimized this variation by irradiating the mice in smaller containers directly under the source.
In reported descriptions of mouse humanization, the number of injected HSPCs needed for substantive engraftment varies from 100 000 to 700 000 per mouse. 5, 32 We have determined that injecting 400 000 HPSCs per mouse results in predictably stable humanization while still allowing for production of large mHM cohorts necessary for multi-arm treatment studies. Our experiments examining the range of HSPCs needed for adequate engraftment indicated that ∼300 000
HSPCs can still humanize mice adequately, especially when using dual HSPC-MSCs (47% mouse bone marrow human HSPCs). However, when we lowered the HSPC number to 150 000, we observed a significant loss of humanization in the form of reduced human CD34
and CD45+ cell populations in the bone marrow Although a high percentage of human bone marrow is necessary in the generation of useful HM, this may not be sufficient as there are additional potentially relevant factors. 12 Myeloid blood cells depend on environmental cytokine cues for their maturation and trafficking, and mouse cytokines largely inhibit proper differentiation. 30 Likewise, human progenitor T cells must migrate from the bone marrow to the thymus to mature, and a mouse thymus lacks the human major histocompatibility complexes to guide proper T cell education and selection, leading to a T cell population that may be largely anergic. There are many strategies being studied to overcome these challenges. Transgenic mouse strains expressing human cytokines can aid in immune cell development and trafficking. Mice can also be engineered to express human major histocompatibility complex molecules, such as the common HLA-A*02:01 variant, allowing them to undergo specific T cell responses to introduced tumor antigens. 38 Engrafted human thymus and bone marrow can help guide T and B cell maturation. 39 Attempts are also underway to harvest cancer patient HSPCs to create HM with an immune system autologous to the implanted tumor.
Despite formidable barriers to achieving a mouse system with appropriate and functional human immune components, these sophisticated mouse models can serve as platforms to advance our understanding of the TME and the development of immune-directed therapies and vaccines in cancer, as well as other areas of human disease. Indeed, much of the initial HM work was conducted to further autoimmunity and stem cell research, and today the increased relevance of the immune system and inflammation in cancer and degenerative human disease has made improved development of these models increasingly germane.
